November 23rd saw the inauguration of STE-1, a brand new €130 Million facility Bayer AG will dedicate to producing parenteral medicines. Following 4 years of construction, the site will initially be dedicated to serving areas with high medical demand, notably products in the field of ophthalmology.
IMA Life contributes to this project with one of the world’s most advanced aseptic processing solutions: INJECTA.
The technology was selected by Bayer for several reasons. Processing flexibility – the ability to adapt to different RTU components for any future developments in production. Filling accuracy – INJECTA performs 100% IPC through fully-robotised check-weighing with single non-conformity rejection capabilities. Unrivalled performance – the advanced robotic technologies at the heart of INJECTA ensure the most efficient, high-speed processing of parenteral products, also in an isolated environment.
Fully integrated into an ultra-modern production line including freeze-drying equipment, INJECTA plays a key role in bringing medicine from concept to market, so as to make them readily available to patients even faster in the future. The STE-1 facility in Berlin is part of a billion-dollar investment program through which Bayer AG aims to strengthen its pharmaceutical production network.
IMA Life Managing Director, Michele Arduini commented: “Being sure of the solid reliability of our solution, coupled with the cutting-edge technologies that represent the real hallmark of INJECTA, we are confident Bayer will achieve their commendable goals, and this makes us even more proud of our role in their global investment program.”
